Transformed Follicular Lymphoma
📧 Sign up to get email alerts when something new happens for Transformed Follicular Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T [Phase 1]
This clinical trial update reports long-term follow-up results from a Phase 1 study of CLBR001 CAR-T cells in relapsed/refractory B-cell lym…
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell Malignancies [NA]
This clinical trial update describes an evaluation of MTM-H-001 injection in adults with relapsed or refractory B-cell lymphomas, with the s…
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients [Phase 1, Phase 2]
This clinical trial update describes a Phase 1/2 study of TC011 for relapsed/refractory large B-cell non-Hodgkin lymphoma, assessing safety …
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies [Phase 1]
Poseida Therapeutics is conducting a Phase 1 trial of P-CD19CD20-ALLO1, an allogeneic CAR-T cell therapy, for several B-cell malignancies an…
-
CLINICAL_TRIALS research · 2026-02-02Clinical Trial Update: Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma [Phase 2]
A Phase 2 clinical trial update describes testing additional drug treatments after CAR T-cell therapy in patients with relapsed or refractor…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-01-29Clinical Trial Update: Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy [Phase 2]
A Phase 2 trial is evaluating whether vaccination with Prevnar 13 before and after CAR-T therapy can enhance cellular and humoral immunity i…
-
CLINICAL_TRIALS research · 2025-09-29Clinical Trial Update: Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy [Phase 2]
A Phase 2 clinical trial evaluating odronextamab for relapsed or refractory diffuse large B-cell lymphoma before and after CAR T-cell therap…
-
CLINICAL_TRIALS trial_result · 2025-08-24Clinical Trial Update: 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers [Phase 1]
This is a Phase 1 clinical trial update for a CAR T cell therapy (19(T2)28z1xx) in various B-cell cancers. The study is sponsored by Memoria…
-
CLINICAL_TRIALS trial_result · 2025-07-16Clinical Trial Update: Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma
A completed follow-up study evaluating a CD19 CAR-T cell therapy engineered to express IL7 and CCL19 for relapsed or refractory B-cell lymph…
-
CLINICAL_TRIALS trial_result · 2024-08-21Clinical Trial Update: ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy) [Phase 1]
The ENABLE-1 Phase 1 trial investigates Toll-like receptor signaling to enhance B-cell lymphoma CAR-T therapy, with the study currently list…
-
CLINICAL_TRIALS trial_result · 2023-08-04Clinical Trial Update: Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL [Phase 1, Phase 2]
Clinical trial update for tazemetostat as a single agent and in combination in B-cell lymphomas and solid tumors completed with results post…
-
CLINICAL_TRIALS trial_result · 2021-11-23Clinical Trial Update: Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma [Phase 1, Phase 2]
This document reports the completion of a Phase 1/2 trial evaluating axicabtagene ciloleucel (KTE-C19) for adults with refractory or relapse…
-
CLINICAL_TRIALS trial_result · 2019-06-28Clinical Trial Update: A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma [Phase 1]
Phase 1 study of GSK2816126 in relapsed/refractory B-cell and solid tumor malignancies terminated; results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2018-03-27Clinical Trial Update: Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma [Phase 2]
A Phase 2 study of alisertib (MLN8237) in adults with aggressive non-Hodgkin lymphoma, including diffuse large B-cell lymphoma and mantle ce…
-
CLINICAL_TRIALS trial_result · 2018-03-27Clinical Trial Update: MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine [Phase 1, Phase 2]
Phase 1/2 trial update of alisertib (MLN8237) in relapsed or refractory aggressive B-cell lymphomas treated with rituximab with or without v…